Idea Thread $PMVP:

Summary – Biotech focused on the development of mutant-selective P53 small molecule re-stabilizers. TP53 = most freq. mutated gene in human cancer. Lead program targets Y220C-mu, present in 0.5-1.0% of all cancers. 2nd program targeting R273H-mu in pre-clin.

Tl;dr Thoughts: A pricey valuation, compelling scientific rationale, IMO strong management/BoD/SAB, interested in initial interim data potentially w/in the next year for lead candidate and monitoring how pre-clinical dev. of 2nd program comes along

Bull Argument: genetically-defined pop., mutant-specific selectivity, differentiated MoA, significant TAM (0.5-1.0% of all cancers for lead), strong management/BoD/SAB, well capitalized

Blue Sky scenario: Initial Ph1/2 results provide support for tumor-agnostic approval (Pivotal Ph1/2 design w AA = quick execution), replicate pre-clinical dev successes in other types of structural mutations (R273H 2-3x TAM potential of Y220C & strengthen confidence in platform)

Bear Arguments: Prev. failures in P53-targeted therapies, unproven MoA, difficulty of reactivator design (?), risks of pursuing tumor-agnostic label & AA, 2nd program fundamentally different problem to lead, Steep Valuation (approx. 1.5B as of 5/6)

Deep dive in progress that'll expand on these points - hopefully will append it to this thread within the next week. Interested to hear other's thoughts as I don't see $PMVP discussed much.